Home / KNBIF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does KNBIF make money? Does KNBIF have pricing power? What's the Earnings Whisper? Will KNBIF profit more as the business scales? What is KNBIF's management track record? Is KNBIF's current price justified?

Kane Biotech Inc.

$0.02 -$0.01 (-30.08%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$0.02

Day Range

$0.02$0.02

Year Range

$0.01$0.03

Market Cap

3.81M

AVG Volume

115.48K

Trailing/Forward PE

-2.05/-

PEG ratio

0.07

Dividend Yield

Next Earnings Date

2026-11-26

Primary Exchange

Other OTC

Revenue (CAD) · TTM

KNBIF Revenue (CAD) · TTM by quarter
Period	Revenue (CAD) · TTM
26 Q2	38.48K
26 Q1	58.34K
25 Q4	427.52K
25 Q3	574.87K
25 Q2	1.85M
25 Q1	2.44M
24 Q4	2.08M
24 Q3	2.01M
24 Q2	1.45M
24 Q1	1.48M

Net Income (CAD) · TTM

KNBIF Net Income (CAD) · TTM by quarter
Period	Net Income (CAD) · TTM
26 Q2	-2.7M
26 Q1	-2.22M
25 Q4	-2.72M
25 Q3	-3.26M
25 Q2	-3.26M
25 Q1	6.28M
24 Q4	6.1M
24 Q3	5.98M
24 Q2	5.21M
24 Q1	-4.94M

Operating Income (CAD) · TTM

KNBIF Operating Income (CAD) · TTM by quarter
Period	Operating Income (CAD) · TTM
26 Q2	-3.14M
26 Q1	-2.63M
25 Q4	-3.11M
25 Q3	-3M
25 Q2	-3.07M
25 Q1	-3.9M
24 Q4	-3.92M
24 Q3	-4.16M
24 Q2	-4.75M
24 Q1	-4.18M

EBITDA (CAD) · TTM

KNBIF EBITDA (CAD) · TTM by quarter
Period	EBITDA (CAD) · TTM
26 Q2	-3.07M
26 Q1	-2.5M
25 Q4	-2.95M
25 Q3	-2.77M
25 Q2	-2.83M
25 Q1	-3.7M
24 Q4	-3.71M
24 Q3	-3.95M
24 Q2	-4.49M
24 Q1	-3.9M

Cash Flows (CAD) · TTM

KNBIF Cash Flows (CAD) · TTM by quarter
Period	Cash Flows (CAD) · TTM
26 Q2	-2.41M
26 Q1	-2.6M
25 Q4	-3.26M
25 Q3	-3.14M
25 Q2	-2.98M
25 Q1	-4.36M
24 Q4	-4.2M
24 Q3	-5.62M
24 Q2	-5.82M
24 Q1	-3.29M

EPS (CAD) · TTM

KNBIF EPS (CAD) · TTM by quarter
Period	EPS (CAD) · TTM
26 Q2	-0.01
26 Q1	-0.01
25 Q4	-0.02
25 Q3	-0.02
25 Q2	-0.02
25 Q1	0.04
24 Q4	0.04
24 Q3	0.03
24 Q2	0.03
24 Q1	-0.04

Expenses (CAD) · TTM

KNBIF Expenses (CAD) · TTM by quarter
Period	Expenses (CAD) · TTM
26 Q2	2.77M
26 Q1	2.27M
25 Q4	2.86M
25 Q3	3.05M
25 Q2	3.68M
25 Q1	4.9M
24 Q4	4.87M
24 Q3	5.19M
24 Q2	5.04M
24 Q1	3.88M

Shares Outstanding (CAD) · TTM

KNBIF Shares Outstanding (CAD) · TTM by quarter
Period	Shares Outstanding (CAD) · TTM
26 Q2	-107.8K
26 Q1	130.93K
25 Q4	0
25 Q3	-71.75K
25 Q2	-187.96K
25 Q1	-633.43K
24 Q4	-710.83K
24 Q3	-765.96K
24 Q2	-855.81K
24 Q1	-683.03K

PE Ratio

KNBIF PE Ratio by quarter
Period	PE Ratio
Sep 25	1.09
Sep 25	0.9
Sep 25	0.91
Sep 25	0.94
Aug 25	0.9
Aug 25	0.9
Aug 25	0.97
Aug 25	1
Aug 25	0.96
Jul 25	0.95
Jul 25	0.95
Jul 25	1.15
Jul 25	1.14
Jun 25	1.11
Jun 25	1.44
Jun 25	1.43
Jun 25	1.18
May 25	1.15
May 25	1.25
May 25	1.4
May 25	1.88
May 25	1.86
Apr 25	2.07
Apr 25	2.15
Apr 25	2.26
Apr 25	2.33
Mar 25	2.14
Mar 25	2.18
Mar 25	2.25
Mar 25	2.06
Feb 25	2.14
Feb 25	2.37
Feb 25	2.41
Feb 25	2.48
Jan 25	2.54
Jan 25	2.56
Jan 25	2.35
Jan 25	2.49
Jan 25	2.49
Dec 24	2.47
Dec 24	2.47
Dec 24	2.9
Dec 24	2.89
Nov 24	3.1
Nov 24	2.73
Nov 24	2.75
Nov 24	2.71
Nov 24	3.45
Oct 24	3.43
Oct 24	3.41
Oct 24	3.43
Oct 24	3.38

Free Cash Flow Yield

KNBIF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-55.68%
Sep 26	-61.99%
Aug 26	-55.51%
Aug 26	-47.36%
Aug 26	-46.99%
Aug 26	-58.87%
Jul 26	-50.54%
Jul 26	-55.97%
Jul 26	-56.26%
Jul 26	-56.05%
Jul 26	-51.62%
Jun 26	-71.85%
Jun 26	-56.82%
Jun 26	-57.43%
Jun 26	-66.09%
May 26	-66.81%
May 26	-66.68%
May 26	-60.9%
May 26	-60.94%
May 26	-44.66%
Apr 26	-55.2%
Apr 26	-68.55%
Apr 26	-68.45%
Apr 26	-65.59%
Mar 26	-61.6%
Mar 26	-62.38%
Mar 26	-53.15%
Mar 26	-51.19%
Feb 26	-50.15%
Feb 26	-50.02%
Feb 26	-47.47%
Feb 26	-46.47%
Jan 26	-46.74%
Jan 26	-44.21%
Jan 26	-47.09%
Jan 26	-49.26%
Jan 26	-51.32%
Dec 25	-50.25%
Dec 25	-49.79%
Dec 25	-49.89%
Dec 25	-52.91%
Nov 25	-52.32%
Nov 25	-51.85%
Nov 25	-49.37%
Nov 25	-59.68%
Oct 25	-45%
Oct 25	-45.03%
Oct 25	-44.95%
Oct 25	-39.8%
Oct 25	-39.95%
Sep 25	-63.54%
Sep 25	-77.12%
Sep 25	-76.72%
Sep 25	-74.12%
Aug 25	-77.39%
Aug 25	-76.93%
Aug 25	-71.28%
Aug 25	-69.24%
Aug 25	-72.65%
Jul 25	-73.13%
Jul 25	-73.27%
Jul 25	-60.65%
Jul 25	-61.1%
Jun 25	-61.82%
Jun 25	-47.78%
Jun 25	-48.32%
Jun 25	-58.27%
May 25	-60.01%
May 25	-55.13%
May 25	-49.28%
May 25	-36.69%
May 25	-37%
Apr 25	-33.29%
Apr 25	-32.07%
Apr 25	-30.5%
Apr 25	-29.55%
Mar 25	-43.79%
Mar 25	-43.03%
Mar 25	-41.75%
Mar 25	-45.47%
Feb 25	-43.8%
Feb 25	-39.65%
Feb 25	-38.94%
Feb 25	-37.93%
Jan 25	-37.02%
Jan 25	-36.6%
Jan 25	-39.89%
Jan 25	-37.68%
Jan 25	-37.76%
Dec 24	-45.18%
Dec 24	-45.27%
Dec 24	-38.49%
Dec 24	-38.7%
Nov 24	-36.06%
Nov 24	-40.89%
Nov 24	-40.66%
Nov 24	-41.18%
Nov 24	-32.39%
Oct 24	-32.52%
Oct 24	-32.74%

Price to Sales

KNBIF Price to Sales by quarter
Period	Price to Sales
Sep 26	79.92
Sep 26	71.79
Aug 26	80.17
Aug 26	93.96
Aug 26	94.71
Aug 26	75.59
Jul 26	88.06
Jul 26	79.51
Jul 26	79.1
Jul 26	79.4
Jul 26	86.2
Jun 26	10.61
Jun 26	13.41
Jun 26	13.27
Jun 26	11.53
May 26	11.4
May 26	11.43
May 26	12.51
May 26	12.5
May 26	17.06
Apr 26	13.8
Apr 26	11.12
Apr 26	11.13
Apr 26	11.62
Mar 26	8.86
Mar 26	8.75
Mar 26	10.26
Mar 26	10.66
Feb 26	10.88
Feb 26	10.91
Feb 26	11.49
Feb 26	11.74
Jan 26	11.67
Jan 26	12.34
Jan 26	11.58
Jan 26	11.07
Jan 26	10.63
Dec 25	3.21
Dec 25	3.24
Dec 25	3.23
Dec 25	3.04
Nov 25	3.08
Nov 25	3.11
Nov 25	3.26
Nov 25	2.7
Oct 25	3.58
Oct 25	3.58
Oct 25	3.58
Oct 25	4.05
Oct 25	4.03
Sep 25	2.81
Sep 25	2.31
Sep 25	2.33
Sep 25	2.41
Aug 25	2.31
Aug 25	2.32
Aug 25	2.5
Aug 25	2.58
Aug 25	2.46
Jul 25	2.44
Jul 25	2.44
Jul 25	2.94
Jul 25	2.92
Jun 25	3.27
Jun 25	4.23
Jun 25	4.18
Jun 25	3.46
May 25	3.36
May 25	3.66
May 25	4.1
May 25	5.5
May 25	5.46
Apr 25	6.07
Apr 25	6.3
Apr 25	6.62
Apr 25	6.83
Mar 25	6.37
Mar 25	6.49
Mar 25	6.69
Mar 25	6.14
Feb 25	6.37
Feb 25	7.04
Feb 25	7.17
Feb 25	7.36
Jan 25	7.54
Jan 25	7.62
Jan 25	7
Jan 25	7.41
Jan 25	7.39
Dec 24	8.89
Dec 24	8.88
Dec 24	10.44
Dec 24	10.38
Nov 24	11.15
Nov 24	9.83
Nov 24	9.88
Nov 24	9.76
Nov 24	12.41
Oct 24	12.36
Oct 24	12.28

Price to Book

KNBIF Price to Book by quarter
Period	Price to Book
Sep 23	1.21
Sep 23	1.3
Sep 23	1.12
Sep 23	1.39
Aug 23	1.52
Aug 23	1.52
Aug 23	1.5
Aug 23	1.5
Jul 23	1.41
Jul 23	1.56
Jul 23	1.45
Dec 21	58.02
Dec 21	58.42
Dec 21	57.04
Dec 21	58.69
Nov 21	63.65
Nov 21	62.9
Nov 21	59.43
Nov 21	54.54
Oct 21	58.85
Oct 21	57.09
Oct 21	60.53
Oct 21	61.06
Oct 21	66.04
Sep 21	62.08
Sep 21	62.5
Sep 21	56.38
Sep 21	57.71
Aug 21	55.03
Aug 21	58.19
Aug 21	59.45
Aug 21	58.81
Jul 21	60.94
Jul 21	61.17
Jul 21	59.94
Jul 21	58.08
Jul 21	58.38
Jun 21	16.16
Jun 21	17.43
Jun 21	17.77
Jun 21	17.65
May 21	19.11
May 21	18.79
May 21	19.53
May 21	20.17
Apr 21	22.32
Apr 21	19.15
Apr 21	18.82
Apr 21	16.96
Apr 21	17.15
Mar 21	8.85
Mar 21	8.19
Mar 21	7.26
Mar 21	7.48
Feb 21	7.36
Feb 21	6.95
Feb 21	7.25
Feb 21	6.67
Jan 21	6.95
Jan 21	7.3
Jan 21	7.22
Jan 21	7.89
Dec 20	7.88
Dec 20	101.7
Dec 20	97.52
Dec 20	101.11
Dec 20	102.67
Nov 20	112.83
Nov 20	102.66
Nov 20	109.45
Nov 20	89.37
Oct 20	91.16
Oct 20	104.19
Oct 20	117.02
Oct 20	106.6
Oct 20	119.74
Sep 20	27.23
Sep 20	28.02
Sep 20	27.97
Sep 20	28.02
Aug 20	26.64
Aug 20	27.96
Aug 20	26.19
Aug 20	28.92
Jul 20	25.85
Jul 20	27.73
Jul 20	29.05
Jul 20	25.2
Jul 20	21.84
Jun 20	16.93
Jun 20	17.87
Jun 20	15.17
Jun 20	14.14
May 20	14.51
May 20	14.57
May 20	14.94
May 20	14.23
May 20	13.08
Apr 20	13.42
Apr 20	13.33

No video analysis for this stock yet. Request one from our team.

News: KNBIF

globenewswire.com · 9 Sep 2026

Kane Biotech to Host Commercial Update Webcast on September 16

Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities

globenewswire.com · 27 Aug 2026

Kane Biotech Announces Second Quarter 2026 Financial Results

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

globenewswire.com · 5 Aug 2026

Kane Biotech Announces Engagement of DNA Advisors

DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives

globenewswire.com · 2 Jul 2026

Kane Biotech Announces Results of Annual and Special Meeting of Shareholders

WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.

seekingalpha.com · 24 Jun 2026